Juli Taylor
Nurse Practitioner · New Castle, INNPI 1568544369
Payments from drug & device makers
Across 94 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$517
- Bayer$93
- Lilly USA, LLC$76
- Neurocrine Biosciences, Inc.$74
- Novo Nordisk$69
- Medtronic$60
- plus $570 from 18 others
What the payments were for
- Food & beverage$1,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $517 |
| Bayer | 6 | $93 |
| Lilly USA, LLC | 5 | $76 |
| Neurocrine Biosciences, Inc. | 4 | $74 |
| Novo Nordisk | 4 | $69 |
| Medtronic | 4 | $60 |
| Lundbeck LLC | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Abbott | 3 | $52 |
| AstraZeneca | 1 | $50 |
| Astellas Pharma US Inc | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Amgen | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 4 | $16 |
| Exact Sciences | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Pfizer | 1 | $12 |
How this compares
$1,459 in reported general payments places this provider in the 75th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valsartan | 14 | $439 |
| Omeprazole | 17 | $347 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $333 |
| Atorvastatin Calcium | 12 | $99 |
| Amlodipine Besylate | 12 | $71 |
| Doxycycline Hyclate | 11 | $61 |
| Lisinopril | 11 | $56 |
| Prednisone | 15 | $18 |
| Levothyroxine Sodium | 11 | $13 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in New Castle
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
- Amber MillerLawrenceburg$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.